BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27236149)

  • 21. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus.
    Nagasaki F; Niitsuma H; Ueno Y; Inoue J; Kogure T; Fukushima K; Shimosegawa T
    Tohoku J Exp Med; 2007 Oct; 213(2):181-6. PubMed ID: 17917412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.
    Xu Z; Dai W; Wu YT; Arshad B; Li X; Wu H; Chen HR; Wu KN; Kong LQ
    Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12799. PubMed ID: 29265535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hepatitis B virus reactivation in a cadaveric renal transplant recipient with entecavir.
    Raheem OA; Hickey DP
    Arab J Nephrol Transplant; 2013 Jan; 6(1):41-4. PubMed ID: 23282233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.
    Liu Z; Jiang L; Liang G; Song E; Jiang W; Zheng Y; Gong C
    J Viral Hepat; 2017 Jul; 24(7):561-572. PubMed ID: 28072494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis.
    Zheng JN; Zou TT; Zou H; Zhu GQ; Ruan LY; Cheng Z; Van Poucke S; Zheng MH
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):979-87. PubMed ID: 27491868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
    Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
    Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin's lymphoma.
    Gozdas HT; Arpaci E
    World J Gastroenterol; 2015 Sep; 21(35):10251-2. PubMed ID: 26401092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
    AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis.
    Huang KW; Tam KW; Luo JC; Kuan YC
    J Clin Gastroenterol; 2017 Jul; 51(6):539-547. PubMed ID: 28067752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
    Huang ZB; Zhao SS; Huang Y; Dai XH; Zhou RR; Yi PP; Chen RC; Li WT; Zhang BX; Li N; Fan XG
    Clin Ther; 2013 Dec; 35(12):1997-2006. PubMed ID: 24238791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
    An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy.
    Chen CH; Hu TH; Hung CH; Wang JH; Lu SN; Lee CM
    J Viral Hepat; 2014 Aug; 21(8):e55-64. PubMed ID: 24766327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
    Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
    Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.